Teligent Inc (TLGT) was Initiated by Raymond James to “Strong Buy” and the brokerage firm has set the Price Target at $11. Raymond James advised their investors in a research report released on Jun 23, 2016.
On the company’s financial health, Teligent Inc reported $0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $-0.04. The company had revenue of $15.70 million for the quarter, compared to analysts expectations of $14.33 million. The company’s revenue was up 46.7% compared to the same quarter last year.
In a different news, on Mar 14, 2016, Jason Grenfell-gardner (CEO) purchased 10,500 shares at $4.82 per share price.
Teligent Inc. formerly IGI Laboratories Inc. is a specialty generic pharmaceutical company. The Company is engaged in the manufacture and development of topical pharmaceutical over-the-counter (OTC) and cosmetic products. The Company under its label sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company has two platforms for growth: developing manufacturing and marketing a range of generic pharmaceutical products under its label in topical injectable complex and ophthalmic dosage forms and managing its contract manufacturing and formulation services business. The Company’s contract manufacturing and development business includes two services: contract formulation and contract manufacturing. The Company’s products are used in a range of applications such as cosmetics and prescription treatment of conditions such as dermatitis psoriasis and eczema.